^
Association details:
| Biomarker: | EGFR amplification |
|---|---|
| Cancer: | Glioblastoma |
| Drug: | lapatinib (EGFR inhibitor, HER2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Lapatinib Ditosylate Before Surgery in Treating Patients With Recurrent High-Grade Glioma
Excerpt:
...- Patient tumor sample must have evidence of EGFR gene amplification by fluorescence in situ hybridization (FISH) using a Clinical Laboratory Improvement Act (CLIA)-certified laboratory assay...
Trial ID:
Source:
Title:
Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors
Excerpt:
...we compared the effects of erlotinib and lapatinib on in vitro cell viability in two EGFR-amplified GBM tumor sphere lines (GS676 and GS600), and again, found that only lapatinib was able to effectively induce cell death...We then compared the effectiveness of different lapatinib dosing schedules on the growth of subcutaneous GS676 GBM xenografts....We observed maximal growth inhibition (Fig. 6D) and caspase activation (Fig. 6E)(Suppl. Fig. 10) in the cohort receiving 1000 mg/kg every fifth day.
DOI:
10.1158/2159-8290.CD-11-0284
